Valuation: Waverley Pharma Inc.

Market Cap 10.8L 8L 7L 6L 6L 7.31Cr 11.07L 75.59L 30.41L 3.86Cr 28.96L 28.34L 12Cr P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 44.79L 32L 28.59L 26.26L 23.85L 30Cr 45.92L 3.14Cr 1.26Cr 16Cr 1.2Cr 1.18Cr 51Cr EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 day+100.00%
1 week+100.00%
Current month+100.00%
1 month+100.00%
3 months+33.33%
6 months+100.00%
1 week 0.02
Extreme 0.02
0.02
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.1
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 01/02/2020
Director of Finance/CFO - 01/01/2020
Director TitleAgeSince
Chairman 79 14/12/2016
Director/Board Member 54 14/12/2016
Director/Board Member - 22/11/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/08/26 Option

Chairman

-1,00,00,000 18.5185%
24/06/24 Other

Director

0 0%
18/08/21 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%+100.00%0.00%-42.86% 8L
-2.43%-4.38%+40.32%+55.64% 6.22TCr
+0.62%+2.58%+20.96%+98.18% 5.53TCr
+0.61%+0.77%+11.13%+69.42% 5.49TCr
+1.61%-3.30%+22.77%+33.16% 4.26TCr
-1.74%-3.02%+13.83%+93.17% 4.11TCr
+3.22%+4.30%+227.37%+776.49% 4.03TCr
+0.57%+24.09%+99.46%+84.11% 3.31TCr
-1.09%+0.69%+14.20%+45.26% 3.26TCr
-4.46%+9.98%-43.92%+320.28% 2.4TCr
Average +9.69%+3.07%+40.61%+153.28% 3.86TCr
Weighted average by Cap. -0.21%+2.12%+45.82%+158.50%

Financials

2024 2025
Net sales 5L 3L 3L 3L 3L 3.22Cr 5L 33.27L 13.38L 1.7Cr 12.75L 12.48L 5.38Cr 13.5L 10L 9L 8L 7L 9.13Cr 13.84L 94.46L 38L 4.82Cr 36.19L 35.42L 15Cr
Net income -9L -7L -6L -6L -5L -6.41Cr -10L -66.28L -26.66L -3.38Cr -25.4L -24.86L -11Cr -5L -4L -3L -3L -3L -3.38Cr -5L -34.94L -14.06L -1.78Cr -13.39L -13.1L -5.65Cr
Net Debt 28.3L 20.22L 18.07L 16.6L 15.07L 19Cr 29.02L 1.98Cr 79.69L 10Cr 75.91L 74.28L 32Cr 33.99L 24.29L 21.7L 19.93L 18.1L 23Cr 34.85L 2.38Cr 95.71L 12Cr 91.17L 89.22L 38Cr
Projected Income Statement - Annual - Waverley Pharma Inc.
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. WAVE Stock